Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs MiMedx Group, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical and biotech industries, managing operational costs is crucial. This chart provides a fascinating comparison of Selling, General, and Administrative (SG&A) expenses between Axsome Therapeutics, Inc. and MiMedx Group, Inc. from 2014 to 2023.

Axsome Therapeutics, Inc.

Axsome Therapeutics has seen a dramatic increase in SG&A expenses, skyrocketing from a modest $1.4 million in 2014 to a staggering $323 million in 2023. This represents an exponential growth of over 23,000%, reflecting the company's aggressive expansion and investment in its operational infrastructure.

MiMedx Group, Inc.

In contrast, MiMedx Group's SG&A expenses have been more stable, growing from $90 million in 2014 to $211 million in 2023, a more moderate increase of 134%. This steadier growth may indicate a more conservative approach to scaling operations.

This comparison highlights the diverse strategies companies employ in managing their operational costs, offering valuable insights into their business models and market positioning.